Drug intelligence / Profile preview

Marathon

Development stage: Preclinical
Lead developer: BIO-XL
Modality: Drug Delivery Systems

Overview

Marathon is a specialized delivery vehicle developed by BIO-XL designed to facilitate mitochondria replacement therapy (MRT). It is engineered to enable the safe and effective administration of healthy mitochondria into target cells to address mitochondrial dysfunction, which is considered a primary driver of cellular aging and age-related decline. By restoring mitochondrial health and bioenergetics, Marathon is intended to support longevity and treat conditions associated with aging. The program is currently in the preclinical/discovery stage of development.

Brand names: Marathon

Beyond the preview

Go deeper on Marathon.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marathon.

Explore the full profile